Shares of Dendreon (NASDAQ:DNDN) climbed in Monday’s pre-market session, after the biotechnology company reported a narrower-than-expected Q4 adjusted loss on revenue that was above Street estimates, and said it will make its Provenge prostate-cancer treatment commercially available in Germany and the U.K. Dendreon (NASDAQ:DNDN) was up 4.2% at $3 in recent pre-market trading. It has a 52-week range of $2.23 to $6.20. The company’s Q4 … Continue reading Pre-Market Movers: Dendreon (NASDAQ:DNDN), Arrowhead Research (NASDAQ:ARWR), Magna International Inc. (NYSE:MGA)

The American Depositary Receipts of AstraZeneca plc (NYSE:AZN) slipped nearly 2% in Monday’s pre-market session after the drugmaker reported that the U.S. FDA approved its Bydureon Pen (2 mg) despite a boxed warning regarding the risk of thyroid C-cell tumors in the use of Bydureon. The Bydureon Pen is an injectable suspension used as a supplement to diet and exercise for patients with Type 2 … Continue reading Monday Morning Roundup: AstraZeneca plc (NYSE:AZN), Rockwood Holdings (NYSE:ROC), The Men’s Wearhouse (NYSE:MW)

Tyco (NYSE:TYC) signed a definitive agreement to sell Tyco Fire & Security Services Korea Co. Ltd. and its subsidiaries (ADT Caps Co., Ltd., Capstec Co., Ltd. and ADT Security Co., Ltd.) that form and operate the company’s South Korean security business (ADT Korea) to The Carlyle Group (CG), in a cash transaction valued at approximately $1.93 billion. The transaction is expected to close in Tyco’s … Continue reading Tyco (NYSE:TYC) Selling Korea Unit to Carlyle Group for $1.93